Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target

2009 ◽  
Vol 24 (4) ◽  
pp. 358-363 ◽  
Author(s):  
Chris J Packard
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Phospholipase A2 ◽  
Therapeutic Target

Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease

2018 ◽  
Vol 24 (3) ◽  
pp. 291-296 ◽  
Author(s):  
Areti Sofogianni ◽  
Stelina Alkagiet ◽  
Konstantinos Tziomalos
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Phospholipase A2 ◽  
Therapeutic Target ◽  
Association Studies ◽  
Genetic Association Studies ◽  
Markers Of Inflammation ◽  
Chd Risk ◽  
Increased Risk

In the last decades, the role of inflammation in the pathogenesis of atherosclerosis has been the topic of intense research. Several markers of inflammation have shown predictive value for first and recurrent coronary events in patients without and with established Coronary Heart Disease (CHD). Among these markers, lipoprotein- associated phospholipase A2 (Lp-PLA2) has recently received considerable attention. In the present review, the potential role of Lp-PLA2 as a marker of CHD risk and as a therapeutic target is discussed. Elevated Lp- PLA2 mass and activity appears to be associated with increased risk for CHD, both in the general population and in patients with established CHD. However, it is unclear whether the measurement of Lp-PLA2 improves risk discrimination when incorporated in models that include traditional cardiovascular risk factors. Moreover, the lack of effect on CHD events of darapladib, a potent, selective Lp-PLA2 inhibitor, in two large, randomized, placebo-controlled trials and the mostly negative findings of genetic association studies suggest that Lp-PLA2 is unlikely to represent a causal factor in atherogenesis. Therefore, it is doubtful whether Lp-PLA2 will constitute a therapeutic target for the prevention of CHD.

scholarly journals Coronary Heart Disease and Genetic Variants with Low Phospholipase A2 Activity

2015 ◽  
Vol 372 (3) ◽  
pp. 295-296 ◽  
Author(s):  
Linda M. Polfus ◽  
Richard A. Gibbs ◽  
Eric Boerwinkle
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Phospholipase A2 ◽  
Genetic Variants ◽  
Phospholipase A2 Activity

scholarly journals Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease

2015 ◽  
Vol 1 (2) ◽  
pp. 105-109
Author(s):  
Jin-Ming Cen ◽  
Jie Cheng ◽  
Qing-Yuan Xiong ◽  
Bai-Qiang Mei ◽  
Wei-Biao Cai ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Phospholipase A2 ◽  
Plasma Lipoprotein

Could lipoprotein-associated phospholipase A2 be used to predict heart failure readmission in coronary heart disease?

2019 ◽  
Vol 493 ◽  
pp. S179
Author(s):  
J. Pego ◽  
A. Carmo ◽  
Â. Maresch ◽  
C. Ferreira ◽  
R. Baptista ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Phospholipase A2

scholarly journals 167: Lipoprotein-associated phospholipase A2 prior to aortic valve surgery as independent predictor of associated coronary heart disease

2013 ◽  
Vol 5 (1) ◽  
pp. 54-55
Author(s):  
Jean-Christophe Charniot ◽  
R Khani-Bittar ◽  
Jea-Paul Albertini ◽  
P Giral ◽  
C Cherfils ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Aortic Valve ◽  
Phospholipase A2 ◽  
Independent Predictor ◽  
Valve Surgery ◽  
Aortic Valve Surgery
Sign in / Sign up

Export Citation Format

Share Document